Literature DB >> 3289572

Lymphotoxin.

N L Paul1, N H Ruddle.   

Abstract

LT was one of the first lymphokines to be described and has been one of the most difficult to fit into a conceptual framework. Now, 20 years after its discovery, its structure, genetic organization, and linkage are well understood in mouse and human, and insight has been gained into its biological role. It is a T cell-derived glycoprotein of 25 kd coded by a gene within the MHC. It is somewhat (35%) structurally homologous to the macrophage product TNF. The genes for LT and TNF are tightly linked, and the proteins share most biological activities and compete for the same cell surface receptor. LT is induced in an antigen-specific MHC restricted fashion from class I and class II restricted T cells. Viral infection is also associated with LT production by lymphoid cells. LT has several effects on target cells including killing, growth stimulation, and induction of differentiation. The mechanism of LT's effects involves receptor binding and internalization and several sequelae including changes in prostaglandins and chromosome integrity. LT probably plays several biological roles. It can contribute to immunoregulation, defense against viruses, parasitic infections, and rejection of tumors. Understanding LT's role in the pathogenesis of diseases of autoimmunity and immune dysregulation will be the key to devising effective regimens for prophylaxis and treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3289572     DOI: 10.1146/annurev.iy.06.040188.002203

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  48 in total

1.  Lymphotoxin activates hepatic T cells and simultaneously induces profound thymic atrophy.

Authors:  A Kusumi; T Abo; T Masuda; K Sugiura; S Seki; T Ohteki; R Okuyama; K Kumagai
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

2.  Tumor necrosis factor receptors in lymphoid tissues and lymphomas. Source and site of action of tumor necrosis factor alpha.

Authors:  B Ryffel; M Brockhaus; U Dürmüller; F Gudat
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

3.  A poly(dA-dT) upstream activating sequence binds high-mobility group I protein and contributes to lymphotoxin (tumor necrosis factor-beta) gene regulation.

Authors:  S J Fashena; R Reeves; N H Ruddle
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

Review 4.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

Review 5.  The interleukins in acquired disease.

Authors:  M Malkovský; P M Sondel; W Strober; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

Review 6.  Interaction of interferon with other cytokines.

Authors:  G Opdenakker; Y Cabeza-Arvelaiz; J Van Damme
Journal:  Experientia       Date:  1989-06-15

7.  Overexpression of the T-cell receptor V beta 3 in transgenic mice increases mortality during infection by enterotoxin A-producing Staphylococcus aureus.

Authors:  Y X Zhao; A Abdelnour; T Kalland; A Tarkowski
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

8.  Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization.

Authors:  S Beissert; M Bergholz; I Waase; G Lepsien; A Schauer; K Pfizenmaier; M Krönke
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

9.  Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.

Authors:  M Sivanandham; S D Scoggin; N Tanaka; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 10.  Genetic polymorphisms and endometrial cancer risk.

Authors:  Larissa A Meyer; Shannon N Westin; Karen H Lu; Michael R Milam
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.